Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$37.02
-0.93 (-2.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-14.0M · quality 29.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
102.8x
↑EV/EBITDA
43.5x
↑ROE
2.4%
↑Gross Margin
25.9%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.7%
FCF CAGR
—
FCF margin
-9.9%
FCF / Net income
-0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $274.2M · net income $36.4M · FCF $-27.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $274.2M | $274.2M | $379.1M | $341.8M | $260.8M |
| Net Income | $36.4M | $36.4M | $85.5M | $108.1M | $98.7M |
| EBITDA | $52.9M | $52.9M | $104.6M | $129.3M | $116.6M |
| EPS | 0.55 | 0.55 | 1.28 | 2.00 | 1.97 |
| Gross Margin | 25.9% | 25.9% | 39.6% | 48.9% | 50.4% |
| Operating Margin | 5.7% | 5.7% | 16.2% | 32.8% | 40.0% |
| Net Margin | 13.3% | 13.3% | 22.6% | 31.6% | 37.9% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 0.00 |
| Current Ratio | 20.60 | 20.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-27.1M | $-27.1M | $5.0M | $-14.0M | $21.6M |
| Returns | |||||
| ROE | 2.4% | 2.4% | 5.7% | 7.4% | 29.8% |
| Valuation | |||||
| P/E | 102.83 | 102.83 | 29.05 | 29.15 | — |
| EV/EBITDA | 43.53 | 43.53 | 22.03 | 22.40 | — |
| P/B | 1.62 | 1.62 | 1.64 | 2.15 | — |
| Growth & Yield | |||||
| Revenue Growth | -27.7% | -27.7% | 10.9% | 31.1% | — |
| EPS Growth | -57.0% | -57.0% | -36.0% | 1.5% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
81.4%
EPS terminal req.
$3.28
Spread vs growth
-138.5%
5Y implied EPS CAGR
48.5%
EPS terminal req.
$3.97
Spread vs growth
-105.6%
10Y implied EPS CAGR
27.8%
EPS terminal req.
$6.40
Spread vs growth
-84.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.5%
Start / end P/E
30.9x → 67.3x
EPS bridge
1.28 → 0.55
Residual
-67.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.